Figure 2 | Scientific Reports

Figure 2

From: A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes

Figure 2

Primary and subgroup analyses for study outcomes of composite cardiovascular diseases, microvascular diseases, and hospitalized hypoglycemia for intermediate-acting human insulin versus long-acting insulin analogue (reference group). IAHI, intermediate-acting human insulin; LAIA, long-acting insulin analogue; aHR, adjusted hazard ratio; CVD, cardiovascular disease; MVD, microvascular disease; DM, diabetes mellitus; N/A, not available. (1) “N/A” indicates “not available”, indicating that the study event number was zero in any comparison subgroup and thus the analysis was not performed. (2) The variables adjusted in these analyses were age, gender, hospital grade, history of retinopathy, and cerebrovascular disease, which are shown to be statistically different between IAHI and LAIA users at baseline (in terms of standardized mean difference value of > 0.1) in Table 1.

Back to article page